Novartis is investing in expanding Pluvicto's label into pre-taxane prostate cancer (SPLASH trial submission pending), and developing next-generation RLT approaches targeting breast cancer and other tumour types positioning it to maintain leadership in the highest-growth oncology peptide segment
TB-500, a synthetic peptide modeled after the active sequence of thymosin 4, shares structural features with its parent compound but has a more targeted molecular footprint (Rahaman et al
Eli Lilly wins approval for new weight-loss pill
Others choose mobile IV therapy as an ongoing wellness option when scheduling clinic visits is difficult
Hashioka, Sadayuki, Youn-Hee Han, Shunsuke Fujii, Takahiro Kato, Akira Monji, Hideo Utsumi, Makoto Sawada, Hiroshi Nakanishi, and Shigenobu Kanba